Bivalirudin started during emergency transport for primary PCI

New England Journal of Medicine

Volumn 369, Issue 23, 2013, Pages 2207-2217

  Steg, Philippe Gabriel ^a,g   Van't Hof, Arnoud ⁱ   Hamm, Christian W ^m   Clemmensen, Peter ^q   Lapostolle, Frédéric ^b   Coste, Pierre ^c   Ten Berg, Jurrien ^k   Van Grunsven, Pierre ^l   Eggink, Gerrit Jan ^j   Nibbe, Lutz ⁿ   Zeymer, Uwe ^o   Dell'Orto, Marco Campo ^m   Nef, Holger ^p   Steinmetz, Jacob ^r   Soulat, Louis ^d   Huber, Kurt ^s   Deliargyris, Efthymios N ^t   Bernstein, Debra ^t   Schuette, Diana ^t   Prats, Jayne ^t   Clayton, Tim ^h   Pocock, Stuart ^h   Hamon, Martial ^e   Goldstein, Patrick ^f   more..

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ Isala Klinieken   (Netherlands)

^j Regionale Ambulancevoorziening IJsselvecht   (Netherlands)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l GGD Gelderland Zuid   (Netherlands)

^m KERCKHOFF HEART CENTER   (Germany)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o KLINIKUM LUDWIGSHAFEN   (Germany)

^p JUSTUS LIEBIG UNIVERSITY   (Germany)

^q UNIVERSITY OF COPENHAGEN   (Denmark)

^r Rigshospitalet   (Denmark)

^s WILHELMINEN HOSPITAL   (Austria)

^t MEDICINES COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; DEATH; EMERGENCY CARE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 84889260178     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311096     Document Type: Article

References (22)

1. Steg PG, James SK, Atar D, et al). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:529-55.
3. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
4. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.
5. Mehta SR, Jolly SS, Cairns J, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012;60:2490-9.
6. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41.
7. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31.
8. Steg PG, van 't Hof A, Clemmensen P, et al. Design and methods of EUROMAX: an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment elevation myocardial infarction transferred for primary percutaneous coronary intervention. Am Heart J 2013 October 16 (Epub ahead of print).
9. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
10. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673-82.
12. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59.
13. Sejersten M, Nielsen SL, Engstrøm T, Jørgensen E, Clemmensen P. Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;103:1635-40.
14. Hirschl MM, Mayr H, Erhart F, et al. Prehospital treatment of patients with acute myocardial infarction with bivalirudin. Am J Emerg Med 2012;30:12-7.
15. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32:1854-64.
16. Hamon M, Pristipino C, Di Mario C, et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention 2013;8:1242- 51.
17. Shahzad A, Cooper RM, Stables RH. Antithrombotic therapy in PCI: why not heparin? EuroIntervention 2013;9:423-6.
18. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-6.
19. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011;123:1745-56.
20. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804.
21. Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5:268-77.
22. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013 September 2 (Epub ahead of print).